The University of Chicago Header Logo

Connection

Ardaman Shergill to Chemotherapy, Adjuvant

This is a "connection" page, showing publications Ardaman Shergill has written about Chemotherapy, Adjuvant.
Connection Strength

0.240
  1. Atezolizumab plus FOLFOX for Stage III Mismatch Repair-Deficient Colon Cancer. N Engl J Med. 2026 Mar 26; 394(12):1155-1166.
    View in: PubMed
    Score: 0.051
  2. Predictive Role of Circulating Tumor DNA in Stage III Colon Cancer Treated With Celecoxib: A Post Hoc Analysis of the CALGB (Alliance)/SWOG 80702 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2026 02 01; 12(2):149-158.
    View in: PubMed
    Score: 0.051
  3. Sex differences in chemotherapy completion, toxicities, and survival in colon cancer: an analysis of 2201 patients from CALGB/SWOG 80702 (Alliance). J Natl Cancer Inst. 2025 Dec 01; 117(12):2643-2652.
    View in: PubMed
    Score: 0.050
  4. Improved Survival With Adjuvant Cyclooxygenase 2 Inhibition in PIK3CA-Activated Stage III Colon Cancer: CALGB/SWOG 80702 (Alliance). J Clin Oncol. 2024 08 20; 42(24):2853-2859.
    View in: PubMed
    Score: 0.045
  5. Preoperative Treatment of Locally Advanced Rectal Cancer. N Engl J Med. 2023 07 27; 389(4):322-334.
    View in: PubMed
    Score: 0.042
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.